Brigantine Advisors Raises Estimates on Hologic (HOLX), Maintains Buy Rating & Price Target
Tweet Send to a Friend
Brigantine Advisors are reiterating their Buy rating and $24 price target on shares of Hologic (NASDAQ: HOLX) as the FDA ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
